Gabriel Pardo to Adolescent
This is a "connection" page, showing publications Gabriel Pardo has written about Adolescent.
Connection Strength
0.152
-
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.
Score: 0.110
-
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15; 341(1-2):22-7.
Score: 0.017
-
Decreased postural balance in multiple sclerosis patients with low disability. Int J Rehabil Res. 2011 Mar; 34(1):53-8.
Score: 0.014
-
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007 Jun; 29(6):1128-45.
Score: 0.011